Press and Updates

AGM DOCUMENTATION

December 20, 2022

GEMINA LABS APPOINTS DR MICHAEL SHANNON AS CHAIR OF CLINICAL ADVISORY BOARD

December 20, 2022

GEMINA LABS ANNOUNCES RESEARCH COLLABORATION ON NEXT GENERATION BIOSENSORS

December 19, 2022

GEMINA’S RECENT INVESTMENT INTO RAPIVD SEES IMMEDIATE PROGRESS

December 13, 2022

GEMINA LABS ANNOUNCES STRATEGIC STAKE IN BRITISH RAPID TEST OPTIMIZER RAPIVD LIMITED

December 7, 2022

GEMINA LABS ENTERS INTO LICENSE AND MANUFACTURING AGREEMENTS

October 6, 2022

GEMINA LABS PRESENTS AT THE H.C. WAINWRIGHT GLOBAL INVESTMENT CONFERENCE

September 12, 2022

GEMINA LABS APPOINTS DIAGNOSTIC EXECUTIVE BRIAN FIRTH AS CHIEF EXECUTIVE OFFICER

September 6, 2022

GEMINA LABS ANNOUNCES CLOSING OF CONCURRENT PRIVATE PLACEMENT

July 11, 2022

GEMINA ANNOUNCES CLOSING OF PROSPECTUS SUPPLEMENT OFFERING AND UPDATE TO CONCURRENT NON-BROKERED PRIVATE PLACEMENT

June 30, 2022

GEMINA ANNOUNCES FILING OF PROSPECTUS SUPPLEMENT

June 24, 2022

GEMINA ANNOUNCES PROPOSED FINANCING OF UP TO $5 MILLION

June 21, 2022

GEMINA LABS APPOINTS POINT-OF-CARE DIAGNOSTIC EXECUTIVE BRIAN FIRTH AS ADVISOR

June 8, 2022

GEMINA LABS ANNOUNCES CE MARK FOR ITS FIRST PRODUCT – THE BEST IN CLASS LEGIO-XTM COVID RAPID ANTIGEN TEST

May 17, 2022

GEMINA LABS COMPLETES SUCCESSFUL HUMAN CLINICAL PERFORMANCE EVALUATION ON ITS LEGIO XTM COVID-19 RAPID ANTIGEN TEST

May 5, 2022

GEMINA LABS NEARS COMPLETION OF PHASE 2 HUMAN PATIENT TESTING FOR INITIAL DIAGNOSTIC TEST

April 28, 2022

GEMINA LABS PROVIDES TECHNICAL DEVELOPMENT UPDATE FOR INITIAL DIAGNOSTIC TEST AND REPORTS FILING OF NEW IP

March 31, 2022

GEMINA LABS ESTABLISHES UK SUBSIDIARY AND APPOINTS DAVID BROWNING AS HEAD OF PRODUCTIZATION

February 23, 2022

GEMINA LABS STRATEGIC UPDATE: FROM PRODUCT TO PLATFORM, GEMINA PROVIDES A TECHNOLOGY ROADMAP

February 15, 2022

GEMINA LABS ANNOUNCES COMPLETION OF SIGNIFICANT DEVELOPMENT STEP FOR ITS SARS-COV-2 RAPID TEST

February 3, 2022

GEMINA LABS ANNOUNCES APPOINTMENT OF SENIOR SCIENTIFIC ADVISER

November 18, 2021

GEMINA LABS ANNOUNCES CLOSING OF OVERSUBSCRIBED PRIVATE PLACEMENT

October 25, 2021

GEMINA LABS ANNOUNCES PRIVATE PLACEMENT

October 20, 2021

GEMINA LABS RECEIVES POSITIVE INITIAL MANUFACTURING RESULTS FOR SARS-COV-2 DIAGNOSTIC TEST

September 20, 2021

GEMINA LABS PROVIDES RESEARCH AND DEVELOPMENT AND CORPORATE UPDATE

September 13, 2021

GEMINA LABS ANNOUNCES RESEARCH AND DEVELOPMENT APPOINTMENTS

August 30, 2021

GEMINA LABS ANNOUNCES LISTING ON THE CANADIAN SECURITIES EXCHANGE

August 10, 2021